COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Survey on Patient Satisfaction Rate for Mirena Use in Heavy Menstrual Bleeding

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00874653
Recruitment Status : Completed
First Posted : April 2, 2009
Last Update Posted : June 23, 2014
Information provided by (Responsible Party):

Brief Summary:

The purposes of this study are:

  • To evaluate patient satisfaction for efficacy and tolerability of heavy menstrual bleeding treatment by Mirena.
  • To collect italian data for Mirena in clinical routine.

Condition or disease Intervention/treatment
Menorrhagia Drug: Levonorgestrel (Mirena, BAY86-5028)

Layout table for study information
Study Type : Observational
Actual Enrollment : 78 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Levonorgestrel Releasing Intrauterine System (MIRENA) in Idiopathic Menorrhagia
Study Start Date : April 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Group 1 Drug: Levonorgestrel (Mirena, BAY86-5028)
Women using Mirena for intrauterine treatment of menorrhagia

Primary Outcome Measures :
  1. The quality of life on the basis of the validated Health-Related Quality of Life questionnaire (HRQL SF-36) [ Time Frame: at 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years to 49 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Women with a diagnosis of idiopathic menorrhagia and Mirena inserted for a period no longer than three months according to the assessment of the investigator will be included in the study

Inclusion Criteria:

  • Women diagnosed with Idiopathic Menorrhagia and Mirena inserted for a period no longer than three months according to the assessment of the investigator and according to the international and national guidelines. These women should also accept to be on contraception during the time period that they have Mirena in situ
  • Body Mass Index = 18-30

Exclusion Criteria:

  • One or more of the following disorders: Current or recurrent pelvic inflammatory disease; infection of the lower genital tract; postpartum endometritis; septic abortion during the past three months; cervicitis; cervical dysplasia; uterine or cervical malignancy; undiagnosed abnormal uterine bleeding; congenital or acquired abnormality of the uterus including fibroids if they distort the uterine cavity; conditions associated with increased susceptibility to infections; acute liver disease or liver tumor; known hypersensitivity to any of the constituents of the product
  • Nulliparity
  • Consumption of Iron, Antiprostaglandins, hormonal drugs and any medication that could effect bleeding should be stopped at least 3 months before the first visit and should not be used during the course of the study.
  • History of diabetes mellitus, cardiovascular disease and thyroid abnormalities
  • Anticoagulation therapy
  • Cancer history including breast cancer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00874653

Layout table for location information
Many Locations, Italy
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Layout table for additonal information
Responsible Party: Bayer Identifier: NCT00874653    
Other Study ID Numbers: 14175
MA0711IT ( Other Identifier: Other company ID )
First Posted: April 2, 2009    Key Record Dates
Last Update Posted: June 23, 2014
Last Verified: June 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Hemorrhage
Uterine Diseases
Pathologic Processes
Menstruation Disturbances
Contraceptive Agents, Female
Contraceptive Agents
Reproductive Control Agents
Physiological Effects of Drugs
Contraceptives, Oral, Synthetic
Contraceptives, Oral